Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti

Jacquet, Vary; Morose, Willy; Schwartzman, Kevin; Oxlade, Olivia; Barr, Graham; Grimard, Franque; Menzies, Dick
January 2006
BMC Public Health;2006, Vol. 6 Issue 1, p209
Academic Journal
Background: Implementation of the World Health Organization's DOTS strategy (Directly Observed Treatment Short-course therapy) can result in significant reduction in tuberculosis incidence. We estimated potential costs and benefits of DOTS expansion in Haiti from the government, and societal perspectives. Methods: Using decision analysis incorporating multiple Markov processes (Markov modelling), we compared expected tuberculosis morbidity, mortality and costs in Haiti with DOTS expansion to reach all of the country, and achieve WHO benchmarks, or if the current situation did not change. Probabilities of tuberculosis related outcomes were derived from the published literature. Government health expenditures, patient and family costs were measured in direct surveys in Haiti and expressed in 2003 US$. Results: Starting in 2003, DOTS expansion in Haiti is anticipated to cost $4.2 million and result in 63,080 fewer tuberculosis cases, 53,120 fewer tuberculosis deaths, and net societal savings of $131 million, over 20 years. Current government spending for tuberculosis is high, relative to the per capita income, and would be only slightly lower with DOTS. Societal savings would begin within 4 years, and would be substantial in all scenarios considered, including higher HIV seroprevalence or drug resistance, unchanged incidence following DOTS expansion, or doubling of initial and ongoing costs for DOTS expansion. Conclusion: A modest investment for DOTS expansion in Haiti would provide considerable humanitarian benefit by reducing tuberculosis-related morbidity, mortality and costs for patients and their families. These benefits, together with projected minimal Haitian government savings, argue strongly for donor support for DOTS expansion.


Related Articles

  • WHO launches new stop TB strategy to fight the global tuberculosis epidemic.  // Indian Journal of Medical Sciences;Mar2006, Vol. 60 Issue 3, p125 

    The article reports that the World Health Organization has launched the Stop TB Strategy to combat the global tuberculosis epidemic (TB). The strategy addresses the challenges faced by several countries on how to continue scaling up TB control activities as well as the spread of TB. It injects...

  • Recent developments in the diagnosis and management of tuberculosis. Sulis, Giorgia; Centis, Rosella; Sotgiu, Giovanni; D'Ambrosio, Lia; Pontali, Emanuele; Spanevello, Antonio; Matteelli, Alberto; Zumla, Alimuddin; Migliori, Giovanni Battista // Primary Care Respiratory Society UK;11/3/2016, p16078 

    Tuberculosis (TB) is a major public health issue worldwide, with ~9.6 million new incident cases and 1.5 million deaths in 2014. The End-TB Strategy launched by the World Health Organization in the context of the post-2015 agenda aims to markedly abate the scourge of TB towards global...

  • WHO calls for extra resources to step up fight against tuberculosis. Zarocostas, John // BMJ: British Medical Journal (International Edition);3/22/2008, Vol. 336 Issue 7645, p631 

    The article focuses on a 2008 report on tuberculosis which was issued by the World Health Organization. In the report the organization indicated that it felt that governments need to scale up national programs to fight and control tuberculosis, which remains a major cause of illness and death...

  • Tuberculosis rates level off, but drug resistance a concern. Arias, Donya C. // Nation's Health;May2007, Vol. 37 Issue 4, p1 

    The article reports on the declining number of cases of tuberculosis around the world. According to the author, it is the first time the global epidemic has leveled off since the World Health Organization declared tuberculosis a public health emergency. In the U.S., tuberculosis rates reached an...

  • Tuberculosis: Current Situation, Challenges and Overview of its Control Programs in India. Sandhu, Gursimrat K. // Journal of Global Infectious Diseases;Apr2011, Vol. 3 Issue 2, p143 

    Tuberculosis (TB) is one of the most ancient diseases of mankind, with molecular evidence going back to over 17,000 years. In spite of newer modalities for diagnosis and treatment of TB, unfortunately, people are still suffering, and worldwide it is among the top 10 killer infectious diseases,...

  • Doubts about DOTS. Davies, G.R.; Squire, S.B. // BMJ: British Medical Journal (International Edition);3/1/2008, Vol. 336 Issue 7642, p457 

    The author reflects on the World Health Organization's strategy to strengthen tuberculosis programs which is called directly observed therapy short course (DOTS). He suggests that the lack of evidence for standardized DOTS based interventions is a concern. He argues that after reviewing research...

  • WHO urges action to fight threat of drug resistant tuberculosis. Zarocostas, John // BMJ: British Medical Journal (International Edition);3/1/2008, Vol. 336 Issue 7642, p465 

    The article focuses on a 2008 announcement and report from the World Health Organization. In the announcement the organization indicated that it wanted governments around the globe to intensify their efforts to fight the growing epidemic of multidrug resistant tuberculosis. The organization...

  • FIDELIS--Innovative Approaches to Increasing Global Case Detection of Tuberculosis. Rusen, I. D.; Enarson, Donald A. // American Journal of Public Health;Jan2006, Vol. 96 Issue 1, p14 

    Tuberculosis was declared a global public health emergency in 1993. In 2003, only 45% of the world's estimated new smear-positive tuberculosis cases were detected--well below the 70% global case detection target set by the World Health Organization. The FIDELIS (Fund for Innovative DOTS...

  • Implications of the impact of prevalence on test thresholds and outcomes: lessons from tuberculosis. Bentley, Tanya G. K.; Catanzaro, Antonino; Ganiats, Theodore G. // BMC Research Notes;2012, Vol. 5 Issue 1, p563 

    Background: With today's rapid advances in technology and understanding of disease, more screening and diagnostic tests have become available in a variety of sociodemographic and clinical settings. This analysis quantifies the impact of varying prevalence rates on test performance for given...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics